Metronidazolo Baxter S.P.A.

Metronidazole, the active ingredient in Metronidazolo Baxter S.P.A., is a nitroimidazole antibiotic presented as an intravenous solution for injection use. It treats anaerobic bacterial infections and certain protozoal diseases in adult and pediatric patients as prescribed by a qualified clinician.

GNH USA supplies Metronidazolo Baxter S.P.A. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is indicated for a range of anaerobic and protozoal infections. It is employed in the following clinical situations: - Anaerobic bacterial infections: eradicates susceptible anaerobes causing intra‑abdominal, skin and soft‑tissue infections. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Clostridioides difficile infection: reduces toxin‑producing C. difficile bacteria in the colon. - Pelvic inflammatory disease: targets mixed anaerobic organisms contributing to PID.

Metronidazole may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional throbbing or tension headache. - Diarrhea: loose stools that may be watery. - Abdominal pain: cramping or discomfort in the abdomen. - Dizziness: light‑headed feeling, especially on standing.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering and detachment. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Neutropenia: marked reduction in white blood cells.

Before initiating Metronidazolo, clinicians should consider several safety measures. - Renal function assessment: adjust therapy in patients with impaired kidney function. - Hepatic monitoring: check liver enzymes periodically during prolonged use. - Alcohol avoidance: advise patients to abstain from alcohol to prevent disulfiram‑like reactions. - Pregnancy caution: use only if the potential benefit outweighs risk, after evaluating alternatives. - Hematologic vigilance: monitor blood counts in patients with pre‑existing blood disorders. - Store at room temperature: keep in original container, protect from moisture and direct light.

Metronidazolo can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole plasma concentrations. - Cimetidine: can increase metronidazole levels, requiring observation for side effects.